Celldex Therapeutics, Inc.CLDXNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, modest growth trend.
Left:
||||
Year-over-year operating income growth rate
Latest
-15.28%
↓ 15% below average
Average (39q)
-13.30%
Historical baseline
Range
High:85.90%
Low:-368.84%
CAGR
+4.0%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -15.28% |
| Q2 2025 | -1.78% |
| Q1 2025 | -11.98% |
| Q4 2024 | -7.48% |
| Q3 2024 | -12.54% |
| Q2 2024 | -14.06% |
| Q1 2024 | 14.74% |
| Q4 2023 | -15.49% |
| Q3 2023 | -24.20% |
| Q2 2023 | -2.26% |
| Q1 2023 | -16.45% |
| Q4 2022 | -0.68% |
| Q3 2022 | 23.90% |
| Q2 2022 | -56.49% |
| Q1 2022 | -14.34% |
| Q4 2021 | 2.32% |
| Q3 2021 | -54.94% |
| Q2 2021 | 19.23% |
| Q1 2021 | 32.86% |
| Q4 2020 | -72.79% |
| Q3 2020 | -26.19% |
| Q2 2020 | 11.67% |
| Q1 2020 | 0.94% |
| Q4 2019 | -9.67% |
| Q3 2019 | 3.37% |
| Q2 2019 | 31.68% |
| Q1 2019 | -48.00% |
| Q4 2018 | -56.13% |
| Q3 2018 | 53.99% |
| Q2 2018 | 85.90% |
| Q1 2018 | -368.84% |
| Q4 2017 | 20.13% |
| Q3 2017 | -10.48% |
| Q2 2017 | 17.61% |
| Q1 2017 | -0.75% |
| Q4 2016 | -16.20% |
| Q3 2016 | 7.33% |
| Q2 2016 | 9.35% |
| Q1 2016 | -6.78% |
| Q4 2015 | -3.30% |